

# **Progress in Allergy**

## **Immunity and Concomitant Immunity in Infectious Diseases**

**31**

**Volume Editor**  
**P. Kallós**

**Series Editors**  
**K. Ishizaka, Baltimore, Md.**  
**P. Kallós, Helsingborg**  
**B.H. Waksman, New York, N.Y.**  
**A.L. de Weck, Bern**



**KARGER**

---

# Immunity and Concomitant Immunity in Infectious Diseases

Volume Editor

*Paul Kallós*, Helsingborg

Contributors

*D. Befus*, Hamilton, Ont.; *J. Bienenstock*, Hamilton, Ont.; *A. Capron*, Lille; *M. Capron*, Lille; *J.-P. Dessaint*, Lille; *C. L. Diggs*, Washington, D. C.; *S. B. Halstead*, Honolulu, Hawaii; *A. Haque*, Lille; *E. E. E. Jarrett*, Glasgow; *J. Mauël*, Epalinges; *H. R. P. Miller*, Edinburgh

14 figures and 13 tables, 1982



---

S. Karger · Basel · München · Paris · London · New York · Sydney

---

## Progress in Allergy

- Vol. 28: Differentiated Lymphocyte Functions.* A.L. de Weck, Bern (ed.) X + 286 p., 47 fig., 26 tab., 1981. ISBN 3-8055-1834-X
- Vol. 29: Ontogeny of the Immune System.* B.H. Waksman, New York, N.Y. (ed.) XII + 268 p., 10 fig., 18 tab., 1981. ISBN 3-8055-2434-X
- Vol. 30: Recent Trends in Allergen and Complement Research.* P. Kallós, Helsingborg (ed.) XIV + 234 p., 56 fig., 32 tab., 1982. ISBN 3-8055-2580-X

---

### National Library of Medicine, Cataloging in Publication

Immunity and concomitant immunity in infectious diseases

Volume editor, Paul Kallós; contributors, D. Befus... [et al.] – Basel; New York: Karger 1982

(Progress in allergy; v. 31)

I. Communicable Disease – immunology. I. Befus, D. II. Kallós, Paul III. Series

W1 PR666F v.31 [WC 1001332]

ISBN 3-8055-3464-7

---

### Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

---

### All rights reserved

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 1982 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)  
Printed in Switzerland by Emmentaler Druck AG, 3550 Langnau  
ISBN 3-8055-3464-7

---

## Immunity and Concomitant Immunity in Infectious Diseases

---

# Progress in Allergy

Vol. 31

Series Editors

*Kimishige Ishizaka*, Baltimore, Md.: *Paul Kallós*, Helsingborg;  
*Byron H. Waksman*, New York, N.Y., and *Alain L. de Weck*, Bern



---

S. Karger · Basel · München · Paris · London · New York · Sydney


---

## Introduction

*Paul Kallós*



*Clemens von Pirquet*  
1874–1929



*Paul Ehrlich*  
1854–1915

The present volume is the first of our series entirely devoted to infectious diseases. This gives me the opportunity to remind our readers that the concept of allergy, as brought forward by *Clemens von Pirquet* [6, 8], originated from his meticulous observations of the course of infectious processes, e.g. that of the first vaccination and revaccination against smallpox. He concluded that ‘Vaccinated individuals react to the vaccine-lymph, syphilitics to the virus of syphilis, sufferers of tuberculosis to tuberculin, those injected with a foreign serum to that serum, in a different manner, than individuals who had no previous contact with these agents. However, they are far from being insensitive. It can only be stated that their reactivity has been changed. To denote the general concept of specifically changed reactivity I propose the term *allergy*. “Allos” indicates the

deviation from the normal behavior, as in the terms allorhythmia and allotropy.' Moreover, he stated that 'the allergic state is not identical with hypersensitivity, but should unite the great complex of phenomena which we presently denote as "immune reactions." Immunity is then a secondary concept and should be limited to processes which lead to full protection of the organism.' It seems to be important to stress that *von Pirquet* realized that in an organism fully and specifically protected from the pathogenic and toxic effects of a microorganism, the same pathogen is able to elicit immediate wheal and erythema, Arthus- or tuberculin-type inflammatory reactions, processes which are presently denoted 'immunopathologic' and play such an important role, for example, in parasitic diseases that are the main subject of the present volume. *von Pirquet* also realized that anaphylaxis, serum sickness and hay fever are allergic disorders, i.e. due to an acquired specific change of reactivity of the organism against the eliciting agent. He assumed that antibodies, such as precipitins, are causatively involved in the pathomechanism of allergic processes.

*von Pirquet's* main concern was the fate of the reactive organism. The aim of his great contemporary, *Paul Ehrlich*, was to explore the function of 'the final biological unit: the cell' especially the 'finest chemistry of cell life'. He summarized and conceptualized his achievements and ideas regarding some cellular events connected with infection and immunity in his Nobel lecture [2]. He postulated that 'partial functions of cells' can only be influenced by agents having chemical affinity to the particular cell. Cells are equipped with an array of chemical structures on their surface, denoted 'side chains' or 'receptors'. Nutrients, toxins, pharmacologically active compounds or microorganisms also possess 'definite chemical structures' and are able to interact with cells possessing receptors which are complementary to them, 'fit one another like lock and key.' Antibodies are preformed cell receptors, antigenic agents stimulate the cells bearing specifically corresponding receptors, to generate them in excess and shed them into the circulation. In other words, *Ehrlich* launched the selective theory of antibody formation. Moreover, the receptor theory explained the specific and selective affinities and actions of pathogenic microorganisms, toxins and other biologically active agents. The assumption that pathogenic microorganisms must possess specific receptors, led *Ehrlich* and his co-workers to the discovery of some features of the nature of the interplay between the immunized host and the specific pathogen. Experimental animals (monkeys or mice) infected with a defined strain of trypanosomes developed immunity within 14 days and the parasites disappeared from

their circulation. After a couple of weeks the animals fell ill again and trypanosomes appeared in their blood. The serum of such animals in relapse was able (i) *in vitro* to agglutinate and kill trypanosomes of the strain used for the original inoculation, and (ii) *in vivo* to protect naive animals against the pathogenic effect of the original strain. The serum had, however, no effect against the trypanosomes of the 'relapse strain'. *Ehrlich* assumed that a number of trypanosomes of the original strain, which withstood the immune attack were able to change the structure of their receptors and, therefore, the antibodies against the original antigenic structure could no longer affect them, they were 'serum resistant'. He stated that 'it is evident from this that the original strain and the relapse strain are not identical, that they must possess two different functional groups (receptors). We have here, therefore, a typical case of an immunologically evoked disappearance of a receptor, with the formation of an entirely new type of receptor. Whether one wishes to describe this change as a mutation or as a variation is surely of small importance, the main point is that it can be induced . . . and is inheritable.'

*Ehrlich's* interest in parasite diseases was evoked by the engagement of his friend *Robert Koch* in the fight against the devastating epidemics, affecting man and domestic animals in Africa. This situation is still prevalent.

I hope that these glimpses into the past show that the genius of *von Pirquet* and *Ehrlich* foreshadowed much of the development in these areas of research. The contributions to the present volume show that progress during the past decade widened our knowledge to an extent nobody could expect, not even the imagination of the great pioneers.

In his contribution to the present volume *Mauël* provides an overview of the 'Effector and escape mechanisms in host-parasite relationships'. The array of humoral and cellular effector mechanisms, such as the protective role of different antibody classes, micro- and macrophages, eosinophils, lymphocytes and their interactions which each other and with the complement system, are highlighted. The escape mechanisms of parasites, such as antigenic variation, as first demonstrated by *Ehrlich*, and the acquisition of host antigenic determinants or those derived from the normal microbial flora of the host, moreover the recently discovered modulation of the immune response of the host by the invading pathogen, are also discussed. In most instances the first encounter between host and parasite takes place on mucosal surfaces. Therefore, it is of great importance that *Befus* and *Bienenstock* discuss in depth the particular conditions relevant for suscepti-



bility or resistance and the adaptive responses of the host and the parasite at this site. In both reviews the importance of the genetic make up of the host for the outcome of the infection is emphasized. Recent observations regarding the functional heterogeneity of macrophages are of great interest in this respect [cf. 3, 5, 9]. *Befus* and *Bienenstock* stress that protective vaccination against certain parasites is ineffective, perhaps impossible, and that in such cases the best possibilities for symbiosis of host and parasite ought to be determined and established. The life cycle of the parasites outside and within their definitive host is quite complicated. Within the host their development and migration expose different tissues to an array of biologically and immunologically active products. *Mauël* and *Befus* and *Bienenstock* provide in their reviews all pertinent data, which are necessary for the understanding of the interactions of host and parasite.

*Jarrett* and *Miller* highlight in their contribution the production and activities of IgE in helminth (mainly nematodes and cestodes) infections. They point out that 'helminth infections are unique in stimulating the production of substantial amounts of IgE'. Helminth allergens, probably glycoproteins of low molecular weight, are the most potent polyclonal activators of IgE production. There is no doubt that helminth-specific IgE antibodies are protective; bound to Fc receptors on eosinophils and macrophages IgE antibodies mediate parasite killing through releasing toxic products from eosinophils and macrophages (e.g. major basic protein of eosinophils and toxic oxygen radicals). Reaction of mast-cell-bound IgE with the corresponding parasite allergen initiates the release of histamine, SRS-A and eosinotactic peptides, which play an important role in worm expulsion. Helminths also produce and release compounds, which are able to degranulate mast cells and basophils independently of IgE. According to *Jarrett* and *Miller* these mast cell activators are at least as potent as 48/80 and their activity results in symptoms which 'mimic' type I allergic reactions. Thus, in helminth-infected subjects specific allergic and pseudoallergic [1] processes occur simultaneously. Further research work concerning the molecular biology of these processes will undoubtedly yield important results for the understanding of the regulation of IgE production and the pathomechanism of type I allergic reactions [cf. 4].

The importance of IgE-dependent cell-mediated destruction of helminths (mainly schistosomes) is further stressed in the contribution by *Capron*, *Dessaint* and *Haque*. Their meticulous research work has conclusively shown that 'anaphylactic antibody' (IgE, in rats also IgG2a and in mice IgG1) dependent killing of parasites by eosinophils and macrophages

(the role of neutrophils is uncertain) is the main protective mechanism against schistosomula. Schistosomula elicit in men and experimental animals a 'dramatic production of anaphylactic antibodies', which are protective against reinfection. Further development of unaffected schistosomula to adult worms (male and female) can occur and they can live, mate and produce a great number of eggs in the host protected against reinfection, the classical example for 'concomitant immunity' [10]. *Capron* et al. thoroughly discuss the complex immunologic and immunopathologic processes induced by schistosomes. They stress that parasite destruction is mainly effected by IgE bearing eosinophil cells and macrophages in vitro as well as in vivo, whereas lymphocytes do not participate in this process. *Capron* et al. emphasize the general importance of the demonstration of IgE-Fc receptors on the surface of eosinophils and macrophages.

Schistosomiasis is an important model disease, since *Warren* [11] demonstrated 25 years ago that mice infected with the free living form of *Schistosoma mansoni*, the miracidium, develop a disease very similar to that of man. Miracidia penetrate the skin, develop to schistosomula, which migrate through the lungs to the portal and splenic vessels and develop to male and female adult worms. These mate and produce a great number of eggs (a worm pair of *S. mansoni* about 300/day). *Warren* showed that about 50% of the eggs are excreted through the gut, the remaining embryonate. The embryo secretes different antigenic products, among others, enzymes (which enable the eggs to pass through the wall of the gut). These antigens induce a vigorous type IV allergic reactivity resulting in granuloma formation around the eggs. The eggs are then destroyed and the granulomas coalesce to fibrotic foci. This granulomatous process is at the bottom of the hepato- and splenomegaly, leading to portal hypertension and esophageal varices, characteristic for *S. mansoni* infection. Here again, a defence mechanism leads to tissue damage, to an 'immunopathologic' process. The cellular and molecular mechanisms involved have been clarified by *Warren* and recently reviewed by him [11].

The present state of immunological research on African trypanosomes is reviewed in the present volume by *C. L. Diggs*. Tremendous progress has been achieved since the days of *Ehrlich*. His fundamental observation concerning the development of 'serum resistance' of trypanosomes and their evasion of the immune response of the host, due to antigenic variation, has been amply confirmed. The variable antigens (receptors) are, according to *Diggs*, glycoproteins of 45,000–90,000 daltons molecular weight, which are 'represented as a loosely connected surface coat outside

the plasma membrane', it is tempting to say that they are true 'side chains'. The molecular mechanisms of antigenic variation, the cellular requirements of the immune response and the immunopathology of trypanosome diseases are thoroughly discussed by *Diggs*. According to him the achievements of the past decade give hope that 'a major impact on the incidence of these protozoan diseases that currently inflict an enormous burden on humankind' can be made in the not too distant future. *Diggs* outlines the avenues of research, which might possibly lead to the development of a protective vaccine.

The last contribution in the present volume by *S. B. Halstead* deals with the immune enhancement of viral infections. As the author points out 'this review probes the domain of virus replication in vivo. It does so by exploring for the first time the growing literature on the enhancement of viral infection or the enhancement of viral disease by antibody or in immune host systems'. The experimental data and clinical observations presented in this review are of very great importance and will certainly 'stimulate discussion and a badly needed critical reevaluation of present day clichés of cellular pathogenesis'.

It was planned to include in this volume a review of malaria immunology, a most important and rapidly growing area of research. Unfortunately, the reviewer Dr. *Anil Jayawardena* of the Yale University, died suddenly of a heart attack at the age of 32 years. He was one of the leading workers in the field of malaria immunology. His untimely death is a great loss.

Finally, I would like to express the deep-felt thanks of the editors to all contributors and to the publisher, Dr. *Thomas Karger*, for their understanding and cooperation.

### References

- 1 Dukor, P.; Kallós, P.; Schlumberger, H.D.; West, G.B.: PAR-Pseudo-allergic reactions. Involvement of drugs and chemicals, vol. 1-3 (Karger, Basel 1980-1982).
- 2 Ehrlich, P.: On partial functions of the cell (Nobel lecture, delivered in Stockholm, December 11, 1908); in *The Collected Papers of Paul Ehrlich*, vol. 3, pp. 183-194 (Pergamon Press, London 1960).
- 3 Forster, O.; Landy, M.: Heterogeneity of mononuclear phagocytes (Academic Press, New York 1981).
- 4 Ishizaka, K.; Kallós, P.; Waksman, B.H.; de Weck, A.L.: Regulation of the IgE antibody response. *Prog. Allergy*, vol. 32 (Karger, Basel 1982).
- 5 Nelson, D.S.: Immunobiology of the macrophage (Academic Press, New York 1976).
- 6 Pirquet, C. von: Allergie. *Münch. med. Wschr.* ii: 1457-1459 (1906).

- 7 Pirquet, C. von: Klinische Studien über Vakzination und vakzinale Allergie (Deuticke, Wien 1907).
- 8 Pirquet, C. von; Schick, B.: Die Serumkrankheit (Deuticke, Wien 1905).
- 9 Skamene, E.; Kongshavn, P. A. L.; Landy, M.: Genetic control of natural resistance to infection and malignancy (Academic Press, New York 1980).
- 10 Smithers, S. R.; Terry, R. J.: Naturally acquired resistance to experimental infection of *S. mansoni* in the rhesus monkey (*Macaca mulatta*). *Parasitology* 55: 701–710 (1965).
- 11 Warren, K. S.: The secret of immunopathogenesis of schistosomiasis. In vivo models. *Immunol. Rev.* 61: 189–213 (1982).

---

## Contents

<i>Introduction</i> <i>P. Kallós, Helsingborg</i> . . . . .	IX
 <i>Effector and Escape Mechanisms in Host-Parasite Relationships</i> <i>Jacques Mauĕl, Epalinges</i> . . . . .	1
Introduction . . . . .	2
Natural (Innate) and Acquired Immunity . . . . .	2
Genetic Aspects of Host Resistance against Parasitic Infections . . . . .	4
Genetic Control of Innate and Acquired Resistance: the <i>Leishmania</i> Model . . . . .	5
Humoral and Cellular Effector Mechanisms of Resistance: General Comments . . . . .	6
Humoral Factors as Effectors of Innate Resistance . . . . .	7
Toxicity of Serum for Parasites . . . . .	7
Correlation between Serum Toxicity for Parasites in vitro, and Infectivity . . . . .	7
Mechanisms of Serum Toxicity . . . . .	8
Humoral Factors as Effectors of Acquired Resistance . . . . .	12
Effector Mechanisms of Resistance Based on the Binding of Antibodies to Critical Parasite Surface Structures . . . . .	13
Antibody-Dependent, Complement-Mediated Parasite Lysis . . . . .	14
Opsonization and Phagocytosis . . . . .	15
Antibody- and Complement-Dependent Leukocyte Cytotoxicity . . . . .	18
Effector Mechanisms in the Gut . . . . .	22
Effector Mechanisms of Resistance not Involving Antibodies . . . . .	25
Contact Cytolysis by T Lymphocytes . . . . .	26
Phagocytosis and Related Events . . . . .	28
Effector Mechanisms of Natural Killer Cells: Soluble Factors Acting at a Distance? . . . . .	33
Parasite Escape Mechanisms . . . . .	36
Immunodepression by Parasites . . . . .	37
Antigenic Variation . . . . .	40

Contents	VI
Antigenic Disguise . . . . .	46
Other Surface Phenomena . . . . .	47
Intracellular Escape Mechanisms . . . . .	50
Summary and Conclusions . . . . .	53
References . . . . .	55

### *Factors Involved in Symbiosis and Host Resistance at the Mucosa-Parasite Interface*

<i>Dean Befus; John Bienenstock, Hamilton, Ont.</i> . . . .	76
I. Introduction . . . . .	77
II. Parasite Antigens in Symbiosis . . . . .	78
A. Parasite Antigens . . . . .	79
1. Nematodes . . . . .	80
2. Platyhelminths . . . . .	83
3. Protozoa . . . . .	85
B. Uptake and Processing of Antigens at Mucosal Sites . . . . .	86
1. Antigen Uptake . . . . .	86
2. Antigen Processing . . . . .	89
III. Host Responses to Mucosal Parasitic Infection . . . . .	90
A. Humoral Responses . . . . .	90
1. IgA . . . . .	90
2. IgE . . . . .	95
3. Complement in Mucosal Resistance . . . . .	100
4. Acute Phase Reactions of Inflammation . . . . .	101
B. Cellular Responses . . . . .	103
1. Lymphocytes . . . . .	103
2. Mast Cells and Basophils . . . . .	110
3. Eosinophils . . . . .	116
4. Macrophages . . . . .	118
5. Goblet Cells and Mucus Secretion . . . . .	121
6. Paneth Cells . . . . .	123
IV. Overview of Mucosal Protective Mechanisms in Parasitic Infections . . . . .	124
V. Symbiosis: Under Threat of Host Resistance . . . . .	127
A. Concomitant Immunity . . . . .	127
B. Antigenic Variation . . . . .	128
C. Immunodepression . . . . .	128
D. Immunological Unresponsiveness at Mucosal Sites . . . . .	130
VI. Mucosal Immunopathology Induced by Parasitic Infections . . . . .	130
VII. Vaccination against Mucosal Parasitic Infections . . . . .	132
VIII. Conclusions . . . . .	133
Taxonomic Glossary . . . . .	134
Acknowledgements . . . . .	135
References . . . . .	135

*Production and Activities of IgE in Helminth Infection**Ellen E. E. Jarrett; Hugh R. P. Miller, Glasgow/Edinburgh* . . . . . 178

Introduction . . . . .	179
Immediate Allergic Phenomena in Worm Parasite Infections. A Historical Perspective of Events before the Discovery of IgE. . . . .	179
Occurrence of Type I Allergic Reactions . . . . .	179
Diagnostic Skin Tests . . . . .	182
Early Observations on Mechanisms of Allergic Reactivity . . . . .	183
Parasite-Specific IgE . . . . .	185
Specific IgE Antibody in Helminth Infections . . . . .	185
Worm Allergens . . . . .	189
Mast Cell Degranulators and Histamine Sensitization in Helminth Infections . . . . .	191
Parasite-Non-Specific IgE . . . . .	193
Potentiated Reagin Response . . . . .	193
Elevation of Total IgE . . . . .	195
Mechanism of Non-Specific IgE Stimulation in Helminth Infections . . . . .	199
Requirement for T Cells . . . . .	199
Factors Produced by T Cells . . . . .	200
Development and Role of IgE B Cells . . . . .	202
Mechanisms in the Mouse . . . . .	203
Role of Parasite-Specific IgE in Protective Immunity to Parasites . . . . .	205
Mast Cells and Basophils in the Parasitized Host . . . . .	205
Occurrence and Consequence of Local Allergic Reactions . . . . .	207
IgE and Antibody-Dependent Cell-Mediated Cytotoxicity . . . . .	209
Role of Parasite-Non-Specific IgE . . . . .	211
Concluding Remarks . . . . .	215
Acknowledgements . . . . .	217
References . . . . .	218

*Antibody-Dependent Cell-Mediated Cytotoxicity against Parasites**André Capron; Jean-Paul Dessaint; Azizul Haque; Monique Capron, Lille* . . . . . 234

Introduction . . . . .	234
Cell Populations Involved in ADCC against Parasites . . . . .	235
ADCC in Schistosome Infection . . . . .	236
Neutrophil-Mediated Killing . . . . .	237
Antibody-Dependent Eosinophil-Mediated Cytotoxicity . . . . .	237
Antibody-Dependent Macrophage-Mediated Cytotoxicity . . . . .	243
ADCC in Nematode Infections . . . . .	249
Eosinophil-Mediated Killing of Nematodes . . . . .	250
Neutrophil-Mediated Killing . . . . .	253
Macrophage-Mediated Killing . . . . .	254
ADCC in Other Parasite Infections . . . . .	255
Evidence for ADCC as a Mechanism of Defence against Parasites . . . . .	256

Conclusion . . . . .	257
References . . . . .	259

### *Immunological Research on African Trypanosomiasis*

<i>Carter L. Diggs, Washington, D. C.</i> . . . .	268
Introduction . . . . .	268
The Diseases and the Parasites . . . . .	269
Antigenic Composition . . . . .	274
Antigenic Variation . . . . .	274
Variant Antigens . . . . .	278
Nonvariant Antigens . . . . .	280
The Immune Response to African Trypanosomes . . . . .	280
Cellular Requirements for Induction of Protective Immunity . . . . .	280
Expression of the Immune Response . . . . .	281
Polyclonality and Macroglobulinemia . . . . .	281
Immunosuppression . . . . .	282
The Role of Specific Cellular Effectors . . . . .	285
Reactivity of Antibodies with Trypanosomes in vitro . . . . .	285
Immunopathology . . . . .	287
Protective Immunity . . . . .	288
Prospects for Immunization against African Trypanosomes . . . . .	289
Conclusions . . . . .	292
Acknowledgments . . . . .	293
References . . . . .	293

### *Immune Enhancement of Viral Infection*

<i>Scott B. Halstead, Honolulu, Hawaii</i> . . . .	301
I. Introduction . . . . .	301
II. Antibody-Mediated Enhancement of Viral Infection . . . . .	303
A. In vitro Observations . . . . .	303
1. Mammalian Mononuclear Phagocytes . . . . .	303
2. Macrophage-Like Cell Lines . . . . .	313
3. Avian Mononuclear Phagocytes . . . . .	316
4. Non-Macrophage Cell Lines . . . . .	322
B. In vivo Observations . . . . .	326
1. Experimental Animals . . . . .	326
2. Man . . . . .	333
III. Under-Neutralization . . . . .	343
IV. Enhancement of Virus Infection in 'Immune' Leukocytes . . . . .	349
V. Discussion . . . . .	350
Acknowledgements . . . . .	354
References . . . . .	354



## Effector and Escape Mechanisms in Host-Parasite Relationships

*Jacques Mauël*

WHO Immunology Research and Training Centre, Institut de Biochimie, Epalinges, Switzerland

### *Contents*

Introduction . . . . .	2
Natural (Innate) and Acquired Immunity . . . . .	2
Genetic Aspects of Host Resistance against Parasitic Infections . . . . .	4
Genetic Control of Innate and Acquired Resistance: the <i>Leishmania</i> Model . . . . .	5
Humoral and Cellular Effector Mechanisms of Resistance: General Comments. . . . .	6
Humoral Factors as Effectors of Innate Resistance . . . . .	7
Toxicity of Serum for Parasites . . . . .	7
Correlation between Serum Toxicity for Parasites in vitro, and Infectivity . . . . .	7
Mechanisms of Serum Toxicity . . . . .	8
Humoral Factors as Effectors of Acquired Resistance . . . . .	12
Effector Mechanisms of Resistance Based on the Binding of Antibodies to Critical Parasite Surface Structures . . . . .	13
Antibody-Dependent, Complement-Mediated Parasite Lysis. . . . .	14
Opsonization and Phagocytosis. . . . .	15
Antibody- and Complement-Dependent Leukocyte Cytotoxicity . . . . .	18
Effector Mechanisms in the Gut . . . . .	22
Effector Mechanisms of Resistance not Involving Antibodies . . . . .	25
Contact Cytolysis by T Lymphocytes . . . . .	26
Phagocytosis and Related Events . . . . .	28
Effector Mechanisms of Natural Killer Cells: Soluble Factors Acting at a Distance? . . . . .	33
Parasite Escape Mechanisms . . . . .	36
Immunodepression by Parasites . . . . .	37
Antigenic Variation . . . . .	40
Antigenic Disguise . . . . .	46
Other Surface Phenomena. . . . .	47
Intracellular Escape Mechanisms . . . . .	50
Summary and Conclusions . . . . .	53
References . . . . .	55